Program
utreglutide
Also written as “GL0034 Dose Level 1”, “GL0034 Dose Level 2” and “GL0034 Dose Level 3”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by Sun Pharmaceutical Industries.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | 22 open or running | phase 2since Dec 5, 2025 | Dec 5, 2025 | Apr 2027phase 2 · NCT07282743 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 25, 2022Named utreglutideINNProposed as its International Nonproprietary Name in WHO's List 126
- Dec 5, 2025First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT07282743 · 285 planned · United States, India
- Jan 27, 2026Phase 1 study in Diabetes Mellitus, Type 2NCT07385547 · 40 planned · United States
Ahead
- Apr 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07282743
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07385547Diabetes Mellitus, Type 2 · United States | 1 | Recruiting | Sep 2026 | 40 |
| NCT07282743Diabetes Mellitus, Type 2 · United States, India | 2 | Recruiting | Apr 2027 | 285 |
How it is read
Names in the registry
- “GL0034 Dose Level 1”, 1 entry
- “GL0034 Dose Level 2”, 1 entry
- “GL0034 Dose Level 3”, 1 entry
- “GL0034 Dose Level 4”, 1 entry
- “GL0034 Dose Level 5”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.